Connectivity-Based Real-Time Functional Magnetic Resonance Imaging Neurofeedback in Nicotine Users: Mechanistic and Clinical Effects of Regulating a Meta-Analytically Defined Target Network in a Double-Blind Controlled Trial.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

One of the fundamental questions in real-time functional magnetic resonance imaging neurofeedback (rt-fMRI NF) investigations is the definition of a suitable neural target for training.

Previously, the researchers applied a meta-analytical approach to define a network-level target for connectivity-based rt-fMRI NF in substance use disorders.

Who Took Part

The age groups tagged for this paper are young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Previously, the researchers applied a meta-analytical approach to define a network-level target for connectivity-based rt-fMRI NF in substance use disorders.

Secondary outcomes were (1) neurofeedback-specific changes in functional connectivity of the target network; (2) changes in smoking behavior and impulsivity measures; and (3) changes in resting-state connectivity profiles.

The subject headings attached to it are Neurofeedback, Magnetic Resonance Imaging, Tobacco Use Disorder, Gyrus Cinguli, Connectome, Nerve Net and Impulsive Behavior.

The authors tagged it with the keywords functional connectivity, functional network, inhibitory control, nicotine dependence and real‐time fMRI.

What This Means in Plain Language

The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2024 (Human brain mapping), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.